Cargando…

Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation

This study aims to provide real-world data about starting-dose of NOACs and dose-adjustment in patients with atrial fibrillation (AF). In fact, even if new oral anticoagulation agents (NOACs) have a predictable effect without need for regular monitoring, dose-adjustments should be performed accordin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gozzo, L., Di Lenarda, A., Mammarella, F., Olimpieri, P. P., Cirilli, A., Cuomo, M., Gulizia, M. M., Colivicchi, F., Murri, G., Kunutsor, S. K., Gabrielli, D., Trotta, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526656/ https://www.ncbi.nlm.nih.gov/pubmed/34667256 http://dx.doi.org/10.1038/s41598-021-99818-4

Ejemplares similares

Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries
por: Olimpieri, P.P., et al.
Publicado: (2020)

How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)
por: Breccia, Massimo, et al.
Publicado: (2020)

Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)
por: Mocini, David, et al.
Publicado: (2021)

Characteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: Insights from the START study
por: De Luca, Leonardo, et al.
Publicado: (2018)

Superiority of Direct Oral Anticoagulants over Vitamin K Antagonists in Oncological Patients with Atrial Fibrillation: Analysis of Efficacy and Safety Outcomes
por: Parrini, Iris, et al.
Publicado: (2022)

Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
por: Jacobs, M. S., et al.
Publicado: (2019)

ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives
por: Nardi, Federico, et al.
Publicado: (2017)

Incidence, Characteristics, and Management of Patients with Recurrent Myocardial Infarctions: Insights from the EYESHOT POST-MI
por: De Luca, Leonardo, et al.
Publicado: (2022)

A Novel Nomogram for Individualized Gonadotropin Starting Dose in GnRH Antagonist Protocol
por: Li, Yubin, et al.
Publicado: (2021)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

How to adjust drug doses in chronic kidney disease
por: Stefani, Maurizio, et al.
Publicado: (2019)

Clinical Impact and Prognostic Role of Triglyceride to High-Density Lipoprotein Cholesterol Ratio in Patients With Chronic Coronary Syndromes at Very High Risk: Insights From the START Study
por: De Luca, Leonardo, et al.
Publicado: (2022)

COVID-19, Vaccines, and Thrombotic Events: A Narrative Review
por: Abrignani, Maurizio G., et al.
Publicado: (2022)

Lower versus higher starting tacrolimus dosing in kidney transplant recipients
por: Chua, Justin C. M., et al.
Publicado: (2022)

Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2022)

Kidney function estimators for drug dose adjustment of direct oral anticoagulants in older adults with atrial fibrillation
por: Villain, Cédric, et al.
Publicado: (2023)

ANMCO POSITION PAPER: Use of sacubitril/valsartan in hospitalized patients with acute heart failure
por: Di Tano, Giuseppe, et al.
Publicado: (2021)

The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

How to Optimize the Administration of Low-Dose Non-vitamin K Antagonist Oral Anticoagulants in Everyday Practice?
por: Undas, Anetta
Publicado: (2022)

ANMCO position paper ‘Appropriateness of prescribing direct oral anticoagulants in stroke and systemic thromboembolism prevention in adult patients with non-valvular atrial fibrillation’
por: Mocini, David, et al.
Publicado: (2022)

Is percutaneous coronary intervention safe during uninterrupted direct oral anticoagulant therapy in patients with atrial fibrillation and acute coronary syndromes?
por: De Luca, Leonardo, et al.
Publicado: (2021)

Effectiveness and Safety of Off-label Dosing of Non–vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients
por: Lee, Kwang-No, et al.
Publicado: (2020)

Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches
por: Garcia-Romeu, Albert, et al.
Publicado: (2021)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
por: García-Romero, N., et al.
Publicado: (2020)

Comparison of two different starting dose of rhFSH in GnRH antagonist protocol for patients with normal ovarian reserve
por: Jia, Zhi-cheng, et al.
Publicado: (2023)

Preemptive Dose Adjustment Effect on the Quality of Anticoagulation Management in Warfarin Patients With Drug Interactions: A Retrospective Cohort Study
por: Fahmi, Amr Mohamed, et al.
Publicado: (2019)

Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2019)

Anticoagulation in Atrial Fibrillation Cardioversion: What Is Crucial to Take into Account
por: Lucà, Fabiana, et al.
Publicado: (2021)

The Safety and Efficacy of Standard-Dose versus Low-Dose Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Left Atrial Appendage Thrombus
por: Feng, Mingjun, et al.
Publicado: (2021)

Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?
por: Hwang, Hui-Jeong, et al.
Publicado: (2023)

Switching pattern and dose adjustment of antidepressants before and during pregnancy
por: Robiyanto, Robiyanto, et al.
Publicado: (2023)

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.
por: Santini, J., et al.
Publicado: (1989)

Some results on the complex adjustment and start-up of the IHEP proton synchrotron
por: Ado, Yu M, et al.
Publicado: (1970)

AORTIC THROMBUS DESPITE THERAPEUTIC DOSE OF ANTICOAGULATION IN A PATIENT POSITIVE FOR COVID-19
por: JACOME, VERONICA, et al.
Publicado: (2022)

Anticoagulants: A Review of the Pharmacology, Dosing, and Complications
por: Alquwaizani, Mohammed, et al.
Publicado: (2013)

Correction: Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
Publicado: (2019)

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care
por: Delesie, Michiel, et al.
Publicado: (2022)

Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine
por: Douwes, Johannes M., et al.
Publicado: (2022)

Alanine Aminotransferase and Risk of the Metabolic Syndrome: A Linear Dose-Response Relationship
por: Kunutsor, Setor K., et al.
Publicado: (2014)

Are doses of lamotrigine or levetiracetam adjusted during pregnancy?
por: Richards, Noni, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n7enqa99jp1hdaq0vncc0sjf87